Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Naomie Kaboré"'
Autor:
Issaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, Moussa Zongo, Nouhoun Barry, Fabrice Anyirékun Somé, Naomie Kaboré, Jean Bosco Ouédraogo
Publikováno v:
The Pan African Medical Journal, Vol 35, Iss 68 (2020)
INTRODUCTION: Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso. We assessed the treatment efficacy, tolerability of these drugs 11 years following its adoption as first
Externí odkaz:
https://doaj.org/article/09e41c213b5a431c81384e00cd477eb2
Autor:
Issaka Zongo, Khalid B. Beshir, Issaka Sagara, Amidou Diarra, Souleymane Dama, Colin J. Sutherland, Oumar B Traore, Bakary Fofana, Aly Kodio, Nouhoun Barry, Amadou Hamidou Togo, Moctar Coulibaly, Aliou Traore, Sam A. Coulibaly, Ouattara S Maurice, Amadou Bamadio, Issiaka Soulama, Nouhoum Diallo, Frederic Nikiema, Jean-Bosco Ouédraogo, Sodiomon B. Sirima, Abdoulaye Djimde, François Dao, Niawanlou Dara, Jean Moise Kaboré, Naomie Kaboré, Fabrice A. Somé, Yves D Compaore, Salif Sombié
Publikováno v:
Antimicrobial Agents and Chemotherapy
A recent randomized controlled trial, the WANECAM (West African Network for Clinical Trials of Antimalarial Drugs) trial, conducted at seven centers in West Africa, found that artemether-lumefantrine, artesunate-amodiaquine, pyronaridine-artesunate,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7470d7461882d18e85d27b95f968b4d2
https://doi.org/10.1128/aac.00873-21
https://doi.org/10.1128/aac.00873-21
Autor:
Jean-Bosco Ouédraogo, Frederic Nikiema, Nouhoun Barry, Fabrice A. Somé, Yves Daniel Compaoré, Moussa Zongo, Issaka Zongo, Naomie Kaboré
Publikováno v:
The Pan African Medical Journal
Introduction Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso. We assessed the treatment efficacy, tolerability of these drugs 11 years following its adoption as first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a5420f0ec0d26ceec5c0346d86626
https://doi.org/10.11604/pamj.2020.35.68.20849
https://doi.org/10.11604/pamj.2020.35.68.20849
Autor:
Issaka Zongo, Abdoulaye Djimde, Karidia Werme, Frederic Nikiema, Naomie Kaboré, Nouhoun Barry, Aminata Fofana, Fabrice A. Somé, Zachari Kabré, Bosco Ouedraogo, Daniel Compaore
Publikováno v:
BMJ Global Health. 2:A14.2-A14
Background Artemisinin combination therapies (ACTs) are widely used for the management of malaria and even tested for chemoprevention. In single episode efficacy studies, these drugs were clinically well tolerated but cardiac effects over repeated tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d09b200254267720e87910b206f5aed6
https://doi.org/10.1136/bmjgh-2016-000260.34
https://doi.org/10.1136/bmjgh-2016-000260.34
Autor:
Fréderic Nikèma, Jean Ouédraogo, Aminata Fofana, Zachari Kabré, Daniel Compaore, Fabrice A. Somé, Abdoulaye Djimde, Naomie Kaboré, Nouhoun Barry, Issaka Zongo
Publikováno v:
BMJ Global Health. 2:A24.3-A25
Background No safe and highly effective malaria vaccine is available today. The treatment drugs currently in use remain insufficient. Moreover, resistance to these drugs makes malaria control difficult. The development of new therapeutic drugs is req
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::297d48ae61bb0acadb2abe110156d1a4
https://doi.org/10.1136/bmjgh-2016-000260.62
https://doi.org/10.1136/bmjgh-2016-000260.62